Artificial Heart Market - Global Forecast 2025-2032

The artificial heart market is undergoing a significant transformation, driven by rapid advancements in device technology, evolving regulatory perspectives, and shifting global production strategies. Senior leaders monitoring this sector are witnessing changes that are redefining cardiovascular support therapies, enabling improved patient experiences and reshaping supply chain priorities.

Market Snapshot: Focused Growth in Artificial Heart Market

The Artificial Heart Market grew from USD 2.82 billion in 2024 to USD 3.14 billion in 2025. It is expected to continue growing at a CAGR of 11.64%, reaching USD 6.81 billion by 2032. This robust growth is fueled by breakthroughs in mechanical circulatory support systems, increasing rates of advanced heart failure, and heightened investment in clinical research. The current environment is characterized by innovation in both total artificial heart and assistive device segments, alongside expanded adoption across key global regions.

Scope & Segmentation

This comprehensive research evaluates the artificial heart market across a dynamic landscape of product types, technologies, applications, and end users. Coverage includes detailed analyses of leading regions and the strategic positioning of major players.

• Type: Total Artificial Heart; Ventricular Assist Device; Biventricular Assist Device; Left Ventricular Assist Device; Right Ventricular Assist Device.
• Application: Bridge to Transplant; Destination Therapy.
• Technology: Axial; Centrifugal; Electromagnetic; Pneumatic.
• End User: Ambulatory Surgical Centers; Hospitals; Specialty Clinics.
• Patient Group: Adults; Pediatrics.
• Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru); Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya); Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan).
• Leading Companies: Abiomed, Inc.; Abbott Laboratories; Medtronic plc; SynCardia Systems, LLC; Carmat SA; Berlin Heart GmbH; Jarvik Heart, Inc.; BiVACOR, Inc.; Sun Medical Technology R&D Co., Ltd.; ReliantHeart, Inc.

Key Takeaways

• Recent advances in biocompatibility and miniaturization have broadened patient eligibility, with total artificial heart designs now supporting both biventricular and left-sided dysfunction.
• Integration of sophisticated control algorithms and sensor technologies is enhancing real-time device adaptability, supporting patient mobility and reducing hospital readmissions.
• Regional production has gained traction due to recent U.S. import tariffs on critical device components, leading to new domestic supplier partnerships and increased automation.
• End-users are shifting procedures from hospitals to ambulatory surgical centers and specialty clinics, supported by remote monitoring infrastructure and streamlined care pathways.
• Strategic collaborations between manufacturers, digital health firms, and academic centers are driving next-generation research, while also influencing value-based reimbursement trends.

Tariff Impact: Shaping Supply Chains and Cost Structures

Introduction of new U.S. import tariffs on essential device parts has driven artificial heart manufacturers to optimize supply chains. The shift towards domestic component production is supporting greater resilience and enabling faster market response, despite initial pressures on costs. Hospitals and clinics are leveraging purchasing consortia and bundled service agreements to manage expense impacts and maintain continuity in patient care.

Methodology & Data Sources

This report utilizes a mixed-methods approach, integrating primary interviews with device experts, peer-reviewed secondary sources, and analysis of international clinical registries. Data validation was achieved by corroborating multiple sources, ensuring accuracy and real-world relevance.

Why This Report Matters

• Informs strategic planning, helping decision-makers benchmark against global peers and emerging technologies.
• Equips stakeholders to navigate evolving regulatory frameworks, tariff-related risks, and new care delivery models.
• Supports investment decisions with actionable insights into localized production trends, technology adoption, and emerging partnerships.

Conclusion

Artificial heart technologies are advancing quickly, fostering improved clinical outcomes and reshaping supply networks. This report provides senior leaders with timely strategic guidance to capitalize on sector advancements and future-proof their market presence.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.